Skip to navigation Skip to content

T-cell lymphoma Program in Pharmaceutical Benefits Scheme (PBS) 012-18051112

Expand/Collapse all sectionsExpand all


This document outlines details of the PBS-subsidised brentuximab vedotin and vorinostat for patients with cutaneous T-cell lymphoma (CTCL), and brentuximab vedotin for patients with peripheral T-cell lymphoma (PTCL).

T-Cell lymphoma and listing dates

Peripheral T-cell lymphoma refers to a group of T-cell lymphomas that develop away from the thymus or bone marrow.

Cutaneous T-cell lymphoma (CTCL) is a specific type of PTCL where the cells attack the skin.

Listing dates are:

  • vorinostat - 1 July 2017
  • brentuximab vedotin - 1 April 2019 (CTCL)
  • brentuximab vedotin - 1 September 2021 (PTCL)

For more information, see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated.

The Resources page contains links to application forms, contact details, item and restriction codes, FAQs, the PBS schedule and the Services Australia websites.

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs